Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Thursday. The firm issued a sell rating on the stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Syros Pharmaceuticals has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Up 7.0 %

Syros Pharmaceuticals stock opened at $0.22 on Thursday. The company has a market cap of $5.89 million, a PE ratio of -0.07 and a beta of 1.31. Syros Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $7.96. The company’s 50-day moving average is $0.35 and its two-hundred day moving average is $2.15.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the business earned ($1.35) earnings per share. Research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the sale, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 12.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Exome Asset Management LLC lifted its position in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals during the third quarter worth about $34,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.